ABG Stock Chart & Stats
€265.40
€5.10(1.96%)
At close: 4:00 PM EDT
€265.40
€5.10(1.96%)
Day’s Range― - ―
52-Week Range€212.90 - €325.25
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€52.52B
Enterprise Value€71.71K
Total Cash (Recent Filing)€2.24B
Total Debt (Recent Filing)€12.39B
Price to Earnings (P/E)23.7
Beta-0.04
Next Earnings
Aug 05, 2026EPS Estimate
3.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.12
Shares Outstanding194,561,070
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€306.52Price Target Upside15.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)15.59
Revenue Forecast (FY)€295.52B
Bulls Say, Bears Say
Bulls Say
Revenue & Earnings MomentumConsistent revenue growth and improving profits indicate durable demand across distribution and pharma services. Strong top-line momentum reinforces scale advantages, helps secure favorable supplier/customer contract terms, and funds reinvestment into logistics and specialty offerings to sustain competitive position.
Margin Expansion (Specialty Mix)Gross profit and margin expansion—partly driven by the OneOncology acquisition—reflect a higher-margin specialty services mix. Structural margin improvement increases operating leverage, helps protect earnings against volume or pricing pressure, and supports continued investment in specialty logistics and commercialization capabilities.
Cash Generation & Capital AllocationStrong cash generation and a clear capital-allocation plan (quarterly FCF, ~$3B guidance, $1B repurchase) provide durable financial flexibility. Reliable cash flow underpins debt repayment, targeted M&A or capex in specialty areas, and shareholder returns while cushioning against cyclical revenue swings.
Bears Say
Elevated LeverageLeverage remains a material structural weakness: elevated debt relative to equity increases interest burden and reduces financial flexibility. High leverage constrains the company's ability to pursue large acquisitions or sustain buybacks if cash generation softens, and raises refinancing risk in adverse scenarios.
Declining Free Cash FlowA sharp TTM free cash flow decline signals higher working-capital needs or timing mismatches. If persistent, weaker FCF limits deleveraging, curtails strategic investments and buybacks, and increases sensitivity to margin compression, reducing the firm's ability to absorb sustained industry headwinds.
Structural Revenue HeadwindsManufacturer WAC price reductions, customer account losses, and faster brand conversions are trimming revenue growth and led to lowered guidance. Persistent pricing pressure or customer shifts could erode the revenue base long-term, requiring sustained margin improvement or cost efficiencies to preserve earnings growth.
Cencora News
ABG FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was €212.90 and its highest was €325.25 in the past 12 months.
What is Cencora’s market cap?
Cencora’s market cap is €52.52B.
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Aug 05, 2026 which is in 2 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on May 06, 2026. The company reported €4.119 earnings per share for the quarter, missing the consensus estimate of €4.178 by -€0.059.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora does not currently pay dividends.
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is 3.77.
How many shares outstanding does Cencora have?
Cencora has 194,561,070 shares outstanding.
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of €4.119 in its last earnings report, missing expectations of €4.178. Following the earnings report the stock price went up 0.311%.
Which hedge fund is a major shareholder of Cencora?
Currently, no hedge funds are holding shares in DE:ABG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€306.52 (15.49% Upside)
€306.52 (15.49% Upside)
Blogger Sentiment
Bullish
DE:ABG Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.49%
12-Months-Change
Fundamentals
Return on Equity
0.75%
Trailing 12-Months
Asset Growth
14.69%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
ABG Company Deck
ABG Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong profitability and cash-generation metrics (EPS growth +7.5%, gross profit +16%, operating income +6%), a raised EPS range, improved operating income guidance, robust international performance, and the resumption of $1B share repurchases against material near-term revenue pressures (reduced consolidated revenue guidance from 7%–9% to 4%–6%) driven by WAC price reductions, account losses and faster mail-order brand conversions. Management highlighted transitory items (weather, COVID vaccine comparisons) and acquisition-related expense impacts but maintained confidence in long-term operating income growth and free cash flow generation.View all DE:ABG earnings summariesABG Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations

ABG Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€306.52
▲(15.49% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Cardinal Health
―
Henry Schein
―
McKesson
―
Prestige Consumer Healthcare
―
Guardian Pharmacy Services, Inc. Class A
―








